New wave of GLP-1 drugs is coming–and they're stronger than Wegovy and Zepbound
5 hours ago
- #weight-loss
- #GLP-1
- #pharmaceuticals
- Terra Field experienced significant weight loss and relief from constant food cravings using Wegovy, a GLP-1 receptor agonist.
- After hitting a plateau, she switched to Zepbound, a dual-target drug, which helped her continue losing weight.
- Many people on GLP-1 drugs see weight loss stagnate, and nearly a quarter experience no benefits, prompting the development of next-generation treatments.
- New drugs like retatrutide target up to three food-related pathways in the brain, showing promising results in clinical trials.
- Eli Lilly's retatrutide led to a 30% body weight loss in 68 weeks in trials, outperforming older drugs like semaglutide and tirzepatide.
- Novo Nordisk is developing CagriSema, a combination of semaglutide and cagrilintide, which targets amylin receptors to enhance weight loss and reduce side effects.
- Extreme weight loss from these drugs can pose health risks, including gallstones, muscle loss, and low blood pressure.
- The rise of these drugs raises ethical questions about affordability, insurance coverage, and the societal implications of choosing one's desired weight.